Explore practical implications of new research in nephrotic syndrome, from renal biopsy and genetic testing to managing ...

Now, it’s worth noting Stock Advisor's total average return is 1,061% — a market-crushing outperformance compared to 192% for ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3 ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, ...

IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Background. A 54-year-old man with multiple myeloma underwent peripheral blood stem cell transplantation (PBSCT) with cells donated by his human leukocyte antigen (HLA)-identical sister. Eight months ...

The heavy metal mercury exists in different forms, which include elemental mercury vapor that forms when fossil fuels and ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle ...

IgA nephropathy can shorten life expectancy by 10 years on average. Life expectancy can depend on several factors, including kidney function at diagnosis, protein levels in the urine, age, other ...

SAN DIEGO & ST. GALLEN, Switzerland, September 26, 2025--(BUSINESS WIRE)--CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice ...